Frequency Therapeutics Announces Hearing Loss Drug Has FDA Fast-Track Designation
In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.